Table 2.
Therapy in the whole sample and according to decompensated and stable heart failure
| Characteristics, % (N) | Whole sample | Decompensated HF | Stable HF | pa | Pb |
|---|---|---|---|---|---|
| N = 1478 | N = 316 | N = 1158 | |||
| Low salt diet | 9.76 (144) | 16.5 (52) | 7.95 (92) | <.0001 | <.0001 |
| Loop diuretic | 64.7 (957) | 86.7 (274) | 58.9 (682) | <.0001 | <.0001 |
| Thiazide diuretic | 5.68 (84) | 5.06 (16) | 5.87 (68) | 0.68 | 0.63 |
| Angiotensin converting enzyme inhibitor (ACEI) | 31.7 (468) | 27.8 (88) | 32.7 (379) | 0.11 | 0.12 |
| Angiotensin receptor blocker (ARB) | 11.2 (165) | 7.91 (25) | 12.1 (140) | 0.05 | 0.03 |
| ACEI or ARB | 42.6 (629) | 35.4 (112) | 44.6 (516) | 0.004 | 0.005 |
| β-blocker (BB) | 48.0 (709) | 48.4 (153) | 47.8 (553) | 0.89 | 0.71 |
| BB and (ACEI or ARB) | 21.9 (324) | 16.8 (53) | 23.4 (271) | 0.01 | 0.02 |
| Aldosterone antagonists | 5.95 (88) | 5.38 (17) | 6.13 (71) | 0.71 | 0.69 |
| Ivabradine | 0.880 (13) | 1.27 (4) | 0.777 (9) | 0.63 | 0.43 |
| Digoxin | 8.32 (123) | 8.23 (26) | 8.38 (97) | 0.99 | 0.96 |
| Nitrates | 13.5 (199) | 17.1 (54) | 12.5 (145) | 0.04 | 0.04 |
| Antiplatelet | 44.3 (652) | 38.5 (121) | 45.9 (531) | 0.02 | 0.02 |
| Statins | 21.4 (316) | 18.2 (57) | 22.4 (259) | 0.12 | 0.14 |
| Anticoagulants | 47.0 (694) | 64.6 (204) | 42.2 (489) | <.0001 | <.0001 |
| Therapeutic anticoagulants | 65.6 (453) | 68.3 (138) | 64.5 (315) | 0.39 | 0.25 |
| Anticoagulant prophylaxis | 34.4 (238) | 31.7 (64) | 35.5 (173) | ||
| Total number of drugs | 8.43 (3.29) | 8.55 (3.41) | 8.39 (3.26) | 0.46 | 0.35 |
a ANOVA test or χ2
b Logistic regression adjusted for age and sex